Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Category: Pharmacology


The All‐Wales Medicines Strategy Group: 18 years’ experience of a National Medicines Optimisation Committee

March 14th 2021

Since 2002, AWMSG has acted as a national medicines optimisation committee in Wales. From the outset, pharmacists and clinical pharmacologists have collaborated closely and shared their complementary expertise to make a much greater contribution to the safe, effective, and cost‐effective use of medicines than either group could have achieved by working separately (British Journal of Clinical Pharmacology)

Categories: Audits, Medication, News, Pharmacology
Tags: AWMSG, Wales

Categories: Audits, Medication, Pharmacology
Tags: AWMSG, Wales

Facing the tidal wave De-risking pharma and creating value for patients

June 17th 2017

This paper examines some of the underlying drivers of the ‘tidal wave’ of diseases, illustrates an alternative way of thinking about the demand challenges and suggest some emerging ways in which industry and the healthcare system can address them (Deloitte)

Categories: News, Pharmacology
Tags: disease

Categories: Pharmacology
Tags: disease

The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis

April 26th 2016

The response to placebo treatment was related to its active comparator, with injectable placebo GLP-1ra showing a relevant response on weight, whereas oral placebo DPP4i showed no significant response. These findings may suggest that subjective expectations influence T2DM treatment efficacy, which can possibly be employed therapeutically (British Journal of Clinical Pharmacology)

Categories: News, Pharmacology
Tags: placebo

Categories: Pharmacology
Tags: placebo

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation

August 18th 2015

Dissociation of the glycemic effect from plasma exposure with gut-restricted Met DR provides strong evidence for a predominantly lower bowel-mediated mechanism of metformin action (Diabetes Care)

Categories: News, Pharmacology
Tags: gut, metformin

Categories: Pharmacology
Tags: gut, metformin

Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given Evening as Compared With Morning in Type 2 Diabetes Mellitus

December 22nd 2014

The PD of insulin glargine differs depending on time of administration. With morning administration insulin activity is greater in the first 0–12 h, while with evening administration the activity is greater in the 12–24 h period following dosing (Diabetes Care)

Categories: News, Pharmacology

Categories: Pharmacology

Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events, and incident cancer

December 8th 2014

There was an association between increasing exogenous insulin dose and increased risk of all-cause mortality, cancer and MACE in people with type 2 diabetes. Limitations of observational studies mean that this should be further investigated using an interventional study design (Diabetes, Obesity and Metabolism)

Categories: News, Pharmacology

Categories: Pharmacology

Glucose Counterregulation in Advanced Type 2 Diabetes Mellitus: Effect of ß-Adrenergic Blockade

August 6th 2014

Overall glucose counterregulation is preserved in advanced T2DM, but the contribution of EGP is diminished. ß-Adrenergic blockade may increase insulin sensitivity at normoglycemia but does not impair glucose counterregulation in T2DM patients, even those with advanced ß-cell failure (Diabetes Care)

Categories: News, Pharmacology

Categories: Pharmacology

Proinsulin-Transferrin Fusion Protein – a Novel Long-acting Insulin Analogue

December 19th 2013

ProINS-Tf exhibited a slow, but sustained, in vivo hypoglycemic efficacy and long plasma half-life. Thus, ProINS-Tf fusion protein can potentially be administered as a prodrug with sustained Tf-mediated activation and selectivity in inhibiting hepatic glucose production (Diabetes)

Categories: News, Pharmacology

Categories: Pharmacology

Diabetes drugs affect hearts of men, women differently

December 17th 2013

In particular, the commonly prescribed diabetes drug metformin had positive effects on heart function in women but not in men, who experienced a shift in metabolism thought to increase the risk of heart failure (Washington University School of Medicine)

Categories: News, Pharmacology

Categories: Pharmacology

DPP-4 inhibitors & GLP-1 reduction in MI size is glucose-dependent

October 22nd 2013

We find that chronic treatment with DPP-4 inhibitors reduced MI size, via the GLP-1 receptor-PKA pathway, in a glucose-dependent manner. Glucose-sensitive cardioprotection of endogenous GLP-1 in diabetic patients may in part explain why intensive control of serum glucose levels has been associated with increased cardiovascular risk (Cardiovascular Diabetology)

Categories: News, Pharmacology

Categories: Pharmacology

Diabetes treatments and cancer risk: drug exposure

September 24th 2013

In this Review, we discuss representation of drug exposure in pharmacoepidemiological investigations of the connection between diabetes drugs and cancer risk. We identify principles that might improve future research (particularly in observational studies), and consider issues related to reverse causation and detection bias (The Lancet Diabetes & Endocrinology)

Categories: News, Pharmacology

Categories: Pharmacology

Linagliptin lowers albuminuria in T2D & renal dysfunction

September 16th 2013

Linagliptin administered in addition to stable RAAS inhibitors led to a significant reduction in albuminuria in patients with type 2 diabetes and renal dysfunction. This observation was independent of changes in glucose level or SBP (Diabetes Care)

Categories: News, Pharmacology

Categories: Pharmacology

Prescribing for Diabetes,England 2005-06 to 2012-13

August 13th 2013

The prescribing data covers prescriptions written by general practitioners, nurses, pharmacists and others working in primary care (Health and Social Care Information Centre)

Categories: News, Pharmacology

Categories: Pharmacology

Glucose-Responsive Microgels & Nanocapsules for Closed-Loop Insulin

August 7th 2013

Acting as a self-regulating valve system, microgels were adjusted to release insulin at basal release rates under normoglycemic conditions and at higher rates under hyperglycemic conditions. These microgels with enzyme nanocapsules facilitate insulin release and result in a reduction of blood glucose levels in a mouse model of type 1 diabetes (Nano)

Categories: News, Pharmacology

Categories: Pharmacology

Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease T2D

April 22nd 2013

DPP-4 inhibitors have some CV protective effects in T2DM in addition to their antidiabetic actions. Additional benefits include lowering the blood pressure, improving the lipid profile and the endothelial dysfunction, decreasing the macrophage-mediated inflammatory response, and reducing myocardial injury. Further investigation in a large cohort is warranted to assess the exact mechanisms of CV protective effects of DPP-4 inhibitors (Journal of Diabetes Research)

Categories: News, Pharmacology

Categories: Pharmacology

Trends in selection & timing of first-line pharmacotherapy in older T2D

April 18th 2013

Metformin has become the most commonly used initial medication for the treatment of diabetes. Although guidelines have evolved to recommend more aggressive initiation and intensification of pharmacotherapy, our results suggest that the time from diagnosis to initiation has increased substantially (Diabetic Medicine)

Categories: News, Pharmacology

Categories: Pharmacology

Mechanisms of action of Sitagliptin Used Alone or With Metformin in T2D

April 17th 2013

M+S combined produce additive effects to 1) reduce FPG and postmeal PG, 2) augment GLP-1 secretion and ß-cell function, 3) decrease plasma glucagon, and 4) inhibit fasting and postmeal EGP compared with M or S monotherapy (Diabetes Care)

Categories: News, Pharmacology

Categories: Pharmacology

Fundamental Role of DPP-4 Inhibitors and GLP-1 Receptor Agonists

April 8th 2013

Based on an expanding and favorable literature describing their use in various patient populations, the guidelines of the American Association of Clinical Endocrinologists (AACE) and the recently updated guidelines from the American Diabetes Association (ADA) assign these agents a central role in the treatment of T2D (Endocrine Practice)

Categories: News, Pharmacology

Categories: Pharmacology

Safety, tolerability, pharmacokinetics, pharmacodynamics empagliflozin

January 29th 2013

Oral administration of empagliflozin at doses of 10 mg, 25 mg or 100 mg once daily over 28 days resulted in significant increases in UGE and reductions in blood glucose compared with placebo, and were well tolerated in patients with type 2 diabetes (Diabetes, Obesity and Metabolism)

Categories: News, Pharmacology

Categories: Pharmacology

The Efficacy and Safety of Insulin Degludec

January 28th 2013

The use of extreme dosing intervals of 8–40 h demonstrates that the daily injection time of IDeg can be varied without compromising glycemic control or safety (Diabetes Care)

Categories: News, Pharmacology

Categories: Pharmacology
  • 1
  • 2
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Novo NordiskAstraZenecaNapp Diabetes

Silver Sponsors

About Ascensia Diabetes CareAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 elderly Empagliflozin exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership